Neuropace Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuropace, Inc. on June 27, 2023, reporting events occurring on June 27 and June 28, 2023. The filing details significant changes in executive leadership, specifically the resignation of the Chief Executive Officer (CEO) and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Resignation of CEO: Michael Favet resigned as CEO and Board member, effective July 10, 2023.
- Appointment of CEO: Joel Becker was appointed as CEO and Board member, effective July 10, 2023.
- Compensation Arrangements:
- Outgoing CEO (Favet): Entering a 12-month consulting agreement at $600/hour. He will receive a pro-rated 2023 bonus. Outstanding equity awards cease vesting after August 1, 2023, but remain exercisable.
- Incoming CEO (Becker): Base salary of $520,000 annually with a target bonus of 75% of base salary. Granted an option to purchase 380,424 shares of common stock. Vesting schedule: 25% on the first anniversary, with the remaining 75% vesting monthly over the subsequent 36 months.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding business strategy. The primary risk disclosed relates to the transition of leadership and the associated compensation costs. The filing notes that the consulting agreement and offer letter are subject to their full text filed as exhibits.
Key Facts for Investor Verification
- Verify the exact effective date of the leadership transition (July 10, 2023) and the interim period coverage.
- Review the full text of the Consulting Agreement (Exhibit 10.1) and Offer Letter (Exhibit 10.2) for specific termination clauses and performance metrics.
- Confirm the impact of the equity grant (380,424 shares) on potential dilution.
- Monitor the company's subsequent filings for any changes in strategic direction under the new CEO.